Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Abstract

Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies. Previously, we established, in a direct xenograft model of PEL-bearing immune-compromised mice, that treatment… (More)
DOI: 10.1172/JCI64503

Topics

7 Figures and Tables

Cite this paper

@article{Bhatt2013EfficaciousPI, title={Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.}, author={Shruti Bhatt and Brittany M. Ashlock and Ngoc L. Toomey and Luis Alonso Diaz and Enrique A. Mesri and Izidore S. Lossos and Juan Carlos Pena Ramos}, journal={The Journal of clinical investigation}, year={2013}, volume={123 6}, pages={2616-28} }